{"title":"欧盟对药品公司的价格操纵进行罚款","authors":"None Laura Howes","doi":"10.1021/cen-10136-buscon17","DOIUrl":null,"url":null,"abstract":"In the first time the regulator has acted against an active pharmaceutical ingredient cartel, the European Commission has fined five companies for price-fixing for the antispasmodic butylscopolamine. Alkaloids of Australia, Alkaloids Corporation, Boehringer Ingelheim, Linnea, and Transo-Pharm will have to pay a total of $14.2 million. A sixth firm, C 2 Pharma, was not fined because it revealed the price-fixing to the commission. All six admitted their involvement and agreed to settle the case. A seventh firm, Alchem, did not settle; the investigation in that case is ongoing.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"49 5","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"EU fines drug companies for price fixing\",\"authors\":\"None Laura Howes\",\"doi\":\"10.1021/cen-10136-buscon17\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the first time the regulator has acted against an active pharmaceutical ingredient cartel, the European Commission has fined five companies for price-fixing for the antispasmodic butylscopolamine. Alkaloids of Australia, Alkaloids Corporation, Boehringer Ingelheim, Linnea, and Transo-Pharm will have to pay a total of $14.2 million. A sixth firm, C 2 Pharma, was not fined because it revealed the price-fixing to the commission. All six admitted their involvement and agreed to settle the case. A seventh firm, Alchem, did not settle; the investigation in that case is ongoing.\",\"PeriodicalId\":9517,\"journal\":{\"name\":\"C&EN Global Enterprise\",\"volume\":\"49 5\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C&EN Global Enterprise\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/cen-10136-buscon17\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10136-buscon17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
In the first time the regulator has acted against an active pharmaceutical ingredient cartel, the European Commission has fined five companies for price-fixing for the antispasmodic butylscopolamine. Alkaloids of Australia, Alkaloids Corporation, Boehringer Ingelheim, Linnea, and Transo-Pharm will have to pay a total of $14.2 million. A sixth firm, C 2 Pharma, was not fined because it revealed the price-fixing to the commission. All six admitted their involvement and agreed to settle the case. A seventh firm, Alchem, did not settle; the investigation in that case is ongoing.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
